Save up to 90% on Emicizumab-KXWH with Coupons, Discount Cards & Patient Assistance Programs

Emicizumab-KXWH is available as a 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL or 150 mg/mL single-dose vial.

Emicizumab-KXWH is a monoclonal antibody that is used for the prevention of bleeding episodes in children and adults with hemophilia A.

Emicizumab-KXWH is a monoclonal antibody that does the same job as factor VIII of bringing two important clotting factors together to continue the clotting process in the blood.

Your dose of Emicizumab-KXWH depends on your weight. The typical starting dose is 3 mg/kg injected under the skin once weekly for the first 4 weeks. Your healthcare provider will have you continue with one of the following maintenance doses, depending on which is best for you:

• 1.5 mg/kg injected under the skin every week, OR
• 3 mg/kg injected under the skin every 2 weeks, OR
• 6 mg/kg injected under the skin every 4 weeks

Emicizumab-KXWH is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Emicizumab-KXWH:

• Injection site reaction (bruising, redness, pain, swelling)
• Headache
• Joint pain
• Diarrhea
• Fever

Serious side effects are rare with Emicizumab-KXWH.

The following medications may interact with Emicizumab-KXWH:

• Clinical experience suggests that a drug interaction exists with Emicizumab-KXWH and aPCC. There is a possibility for an increased risk of clotting with rFVIIa or FVIII with Emicizumab-KXWH based on preclinical experiments.

Various FDA-approved generic manufacturers

It is not known if Emicizumab-KXWH may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with Emicizumab-KXWH.

• Hemlibra